InvestSMART

EMvision Medical Devices Limited (ASX: EMV) - Announcements

Current share price for EMV : $1.750 0.025 (1.41%)+

ASX company news and announcements for EMvision Medical Devices Limited (EMV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All EMvision Medical Devices Limited (EMV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than EMvision Medical Devices Limited (EMV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for EMvision Medical Devices Limited (EMV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$163 Clinical Trial Progress & ASA Milestone Achieved 27 Jul 2023 8:20AM $1.210 $1.750 risen by 44.63%
$163 Recruitment at Royal Melbourne Hospital Commences 29 Jun 2023 8:20AM $1.185 $1.750 risen by 47.68%
$163 $1.75M Manufacturing Grant Payment Received 13 Jun 2023 9:05AM $1.265 $1.750 risen by 38.34%
$163 Leadership Transition 31 May 2023 9:00AM $1.405 $1.750 risen by 24.56%
$163 Stage 2 of Clinical Trial Activated 29 May 2023 8:19AM $1.545 $1.750 risen by 13.27%
$163 Change of Director's Interest Notice 5 May 2023 1:22PM $1.590 $1.750 risen by 10.06%
$163 Cleansing Notice 5 May 2023 1:21PM $1.590 $1.750 risen by 10.06%
$163 Application for quotation of securities - EMV 5 May 2023 1:19PM $1.590 $1.750 risen by 10.06%
$163 Quarterly Activities/Appendix 4C Cash Flow Report 27 Apr 2023 8:03AM $1.520 $1.750 risen by 15.13%
$163 Notification regarding unquoted securities - EMV 24 Apr 2023 3:37PM $1.495 $1.750 risen by 17.06%
$163 Product Development Milestones & Grant Funding Achieved 17 Apr 2023 8:21AM $1.725 $1.750 risen by 1.45%
$163 Cleansing Notice 3 Apr 2023 8:24AM $1.350 $1.750 risen by 29.63%
$163 Application for quotation of securities - EMV 3 Apr 2023 8:24AM $1.350 $1.750 risen by 29.63%
$163 Clinical Advisory Board Appointment 14 Mar 2023 8:13AM $1.305 $1.750 risen by 34.10%
$163 CEO Half-Year Update 28 Feb 2023 8:03AM $1.435 $1.750 risen by 21.95%
$163 Half Yearly Report and Accounts 28 Feb 2023 7:51AM $1.435 $1.750 risen by 21.95%
$163 Clinical Trial Stage 1 Enrolment Completed 21 Feb 2023 8:03AM $1.475 $1.750 risen by 18.64%
$163 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2023 7:42AM $1.705 $1.750 risen by 2.64%
$163 Trial Progressing on Target and ASA Milestone Achieved 25 Jan 2023 9:13AM $1.700 $1.750 risen by 2.94%
$163 Change of Director's Interest Notice X 6 1 Dec 2022 4:49PM $2.085 $1.750 fallen by 16.07%
$163 Notification regarding unquoted securities - EMV 1 Dec 2022 4:46PM $2.085 $1.750 fallen by 16.07%
$163 $8.8m In Non-Dilutive Funding To Be Received This Quarter 1 Dec 2022 8:19AM $2.130 $1.750 fallen by 17.84%
$163 EMVision Commences Clinical Trial 30 Nov 2022 8:19AM $2.010 $1.750 fallen by 12.94%
$163 Results of Annual General Meeting 16 Nov 2022 11:46AM $1.820 $1.750 fallen by 3.85%
$163 AGM Chairman Address and Presentation 16 Nov 2022 10:13AM $1.910 $1.750 fallen by 8.38%

151 - 175 of 371 results

Page 7 of 15

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.